Lördag 21 December | 18:21:27 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2023-02-22 - Bokslutskommuniké 2022
2022-12-05 - Extra Bolagsstämma 2022
2022-07-21 - Kvartalsrapport 2022-Q2
2022-05-31 - Årsstämma
2022-05-06 - X-dag ordinarie utdelning KARO 0.00 SEK
2022-02-25 - Bokslutskommuniké 2021
2021-10-28 - Kvartalsrapport 2021-Q3
2021-07-22 - Kvartalsrapport 2021-Q2
2021-04-23 - X-dag ordinarie utdelning KARO 0.00 SEK
2021-04-21 - Årsstämma
2021-04-21 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-10-30 - Kvartalsrapport 2020-Q3
2020-07-21 - Kvartalsrapport 2020-Q2
2020-05-25 - Årsstämma
2020-04-30 - X-dag ordinarie utdelning KARO 0.00 SEK
2020-04-29 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-11-15 - Kvartalsrapport 2019-Q3
2019-09-20 - Extra Bolagsstämma 2019
2019-07-19 - Kvartalsrapport 2019-Q2
2019-05-17 - X-dag ordinarie utdelning KARO 0.00 SEK
2019-05-16 - Årsstämma
2019-04-26 - Kvartalsrapport 2019-Q1
2019-02-14 - Bokslutskommuniké 2018
2018-11-01 - Kvartalsrapport 2018-Q3
2018-07-19 - Kvartalsrapport 2018-Q2
2018-05-04 - X-dag ordinarie utdelning KARO 0.30 SEK
2018-05-03 - Årsstämma
2018-04-26 - Kvartalsrapport 2018-Q1
2018-02-22 - Bokslutskommuniké 2017
2017-12-08 - Extra Bolagsstämma 2017
2017-11-02 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-05-12 - X-dag ordinarie utdelning KARO 0.28 SEK
2017-05-12 - X-dag bonusutdelning KARO 0.22
2017-05-11 - Årsstämma
2017-05-10 - Kvartalsrapport 2017-Q1
2017-02-28 - Bokslutskommuniké 2016
2016-10-27 - Kvartalsrapport 2016-Q3
2016-07-15 - Kvartalsrapport 2016-Q2
2016-05-13 - X-dag ordinarie utdelning KARO 0.00 SEK
2016-05-12 - Årsstämma
2016-05-12 - Kvartalsrapport 2016-Q1
2016-03-16 - Extra Bolagsstämma 2016
2016-02-12 - Bokslutskommuniké 2015
2015-10-29 - Kvartalsrapport 2015-Q3
2015-08-26 - Split KARO 20:1
2015-07-10 - Kvartalsrapport 2015-Q2
2015-04-30 - X-dag ordinarie utdelning KARO 0.00 SEK
2015-04-29 - Årsstämma
2015-04-29 - Kvartalsrapport 2015-Q1
2015-02-13 - Bokslutskommuniké 2014
2014-10-29 - Kvartalsrapport 2014-Q3
2014-07-11 - Kvartalsrapport 2014-Q2
2014-05-09 - X-dag ordinarie utdelning KARO 0.00 SEK
2014-05-08 - Årsstämma
2014-05-08 - Kvartalsrapport 2014-Q1
2014-03-17 - Extra Bolagsstämma 2014
2014-02-13 - Bokslutskommuniké 2013
2013-10-25 - Kvartalsrapport 2013-Q3
2013-07-12 - Kvartalsrapport 2013-Q2
2013-05-08 - X-dag ordinarie utdelning KARO 0.00 SEK
2013-05-07 - Årsstämma
2013-05-07 - Kvartalsrapport 2013-Q1
2013-03-13 - 15-7 2013
2013-02-12 - Bokslutskommuniké 2012
2013-02-12 - Analytiker möte 2013
2012-11-19 - Extra Bolagsstämma 2012
2012-10-24 - Kvartalsrapport 2012-Q3
2012-07-13 - Kvartalsrapport 2012-Q2
2012-06-12 - Årsstämma
2012-04-30 - X-dag ordinarie utdelning KARO 0.00 SEK
2012-04-27 - Kvartalsrapport 2012-Q1
2012-02-08 - Bokslutskommuniké 2011
2011-11-29 - 15-7 2011
2011-10-25 - Kvartalsrapport 2011-Q3
2011-07-13 - Kvartalsrapport 2011-Q2
2011-04-28 - X-dag ordinarie utdelning KARO 0.00 SEK
2011-04-27 - Årsstämma
2011-04-27 - Kvartalsrapport 2011-Q1
2011-02-09 - Bokslutskommuniké 2010
2010-10-26 - Kvartalsrapport 2010-Q3
2010-07-13 - Kvartalsrapport 2010-Q2
2010-04-26 - X-dag ordinarie utdelning KARO 0.00 SEK
2010-04-23 - Årsstämma
2010-04-22 - Kvartalsrapport 2010-Q1
2010-02-09 - Bokslutskommuniké 2009
2009-10-22 - Kvartalsrapport 2009-Q3
2009-07-14 - Kvartalsrapport 2009-Q2
2009-04-27 - X-dag ordinarie utdelning KARO 0.00 SEK
2009-04-24 - Årsstämma
2009-04-22 - Kvartalsrapport 2009-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Karo Pharma verkar inom vardagshälsa. Bolaget äger och kommersialiserar receptbelagda läkemedel och receptfria konsumentprodukter som säljs i apotek och detaljhandel samt via online-kanaler. Genom direkta försäljningsorganisationer och distributörsnätverk är bolagets produkter tillgängliga globalt, men med dess kärnverksamhet i Europa. Bolaget har sitt huvudkontor i Stockholm.
2022-09-26 08:30:00

On 16 August 2022, Karo Intressenter AB[1] ("Karo Intressenter") announced a public cash offer to the shareholders in Karo Pharma Aktiebolag ("Karo Pharma" or the "Company") to acquire the shares in Karo Pharma not already held by Karo Intressenter at a price of SEK 60 per share (the "Offer"). On 19 September 2022, Karo Intressenter announced the outcome of the Offer, that they completed the Offer and that Karo Intressenter thereby, at the time of the publication of the announcement, controlled in total approximately 93.7 percent of the total number of shares and votes in Karo Pharma. At the same time, Karo Intressenter announced that the acceptance period was extended until 7 October 2022. Karo Intressenter has initiated compulsory redemption of the remaining shares in Karo Pharma.

Karo Intressenter, holding approximately 93.7 percent of the shares and votes in Karo Pharma, has initiated compulsory redemption of the remaining shares in Karo Pharma. Karo Pharma has today notified the minority shareholders that compulsory redemption has been requested and that the minority shareholders will have the opportunity to, no later than two weeks from today's date, in writing report that they wish to bring their own action and state a joint arbitrator. If shareholders to which the redemption claim is directed at does not submit the name of a joint arbitrator within the prescribed time, the Board of Directors of Karo Pharma will file an application with the Swedish Companies Registration Office for appointment of a trustee. The trustee shall appoint a joint arbitrator for the minority shareholders and shall safeguard the interest of absent shareholders in the dispute.

For further information, please contact:
Christoffer Lorenzen, CEO, +46 73-501 76 20, christoffer.lorenzen@karopharma.com
Jon Johnsson, CFO, +46 73-507 88 61, jon.johnsson@karopharma.com

The information was submitted for publication by the contact persons set out above, at 26 September CEST on 08:30 2022.

About Karo Pharma

Karo Pharma offers "Smart choices for everyday healthcare". We own and commercialize reliable original brands within prescription drugs and over-the-counter consumer products. Our products are available in over 90 countries with the core in Europe and the Nordics region. The headquarter of Karo Pharma is in Stockholm and the company is listed on Nasdaq First North Growth Market.

Certified Adviser

Erik Penser Bank AB is the Karo Pharma's Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email:certifiedadviser@penser.se.

[1] A Swedish private limited liability company (Sw. privat aktiebolag) controlled by EQT VIII, registered with the Swedish Companies Registration Office with corporate registration number 559160-9416.